Revlimid (Lenalidomide) (Capsules)


Indications and Reactions:

Role Indications Reactions
Primary
Plasma Cell Myeloma 81.6%
Myelodysplastic Syndrome 10.0%
Product Used For Unknown Indication 1.6%
Chronic Lymphocytic Leukaemia 1.5%
Amyloidosis 0.6%
Myelofibrosis 0.6%
Lymphoma 0.5%
Non-hodgkin's Lymphoma 0.5%
5Q Minus Syndrome 0.4%
Acute Myeloid Leukaemia 0.3%
Diffuse Large B-cell Lymphoma 0.3%
Hodgkin's Disease 0.3%
Lymphocytic Leukaemia 0.3%
Mantle Cell Lymphoma 0.3%
Multiple Myeloma 0.3%
Leukaemia 0.2%
Neoplasm 0.2%
Plasma Cell Leukaemia 0.2%
B-cell Lymphoma Stage Iii 0.1%
Chronic Lymphocytic Leukaemia Refractory 0.1%
White Blood Cell Count Decreased 10.4%
Rash 8.5%
Pneumonia 7.9%
Thrombosis 7.9%
Drug Dose Omission 6.5%
Platelet Count Decreased 6.5%
Thrombocytopenia 5.4%
Full Blood Count Decreased 5.2%
Vomiting 4.6%
Diarrhoea 4.4%
Pruritus 4.4%
Pancytopenia 4.2%
Fatigue 4.0%
Plasma Cell Myeloma 3.3%
Weight Decreased 3.3%
Neuropathy Peripheral 3.1%
Neutropenia 2.7%
Pain In Extremity 2.7%
Haemoglobin Decreased 2.5%
Pyrexia 2.5%
Secondary
Plasma Cell Myeloma 66.7%
Myelodysplastic Syndrome 33.3%
Skin Exfoliation 50.0%
Treatment Failure 50.0%
Concomitant
Plasma Cell Myeloma 100.0%
Vomiting 100.0%

Drug Data